Nordic Pharma sues Hims & Hers over counterfeit formulation of Wegovy.

Novo Nordisk announced on Monday that it has filed a lawsuit against online telemedicine provider Hims & Hers, accusing them of marketing cheaper, unapproved generic versions of their new weight loss drug Wegovy in the United States on a large scale. Novo Nordisk is seeking a permanent injunction from the court to prevent Hims from selling the infringing version of the drug and is also seeking compensation for damages. Novo Nordisk accused Hims in a statement of "misleading patients and putting their health at risk" because the safety, effectiveness, and quality of these generic versions have not been verified by US regulatory authorities. This marks an escalation in the dispute between Novo Nordisk and Hims. Hims announced last Saturday that they will stop offering the generic version of their new weight loss oral drug following scrutiny from federal regulatory agencies and legal threats from the Danish pharmaceutical company. Hims had originally planned to sell the oral drug for as low as $49 for the first month, which is about $100 less than the approved Wegovy oral drug from Novo Nordisk.